Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus QMF149 in poorly controlled asthma
NL-OMON47663Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate, atectura breezhaler and salmeterol + fluticasone in asthma (5 arms), sponsored by Novartis. Started Apr 2016; status: active, not recruiting.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoateatectura breezhalersalmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON47663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47663.